Depression is one of the most widely misunderstood psychological conditions in the modern world. A lot of people simply assume that it’s about people feeling said. Unfortunately, it goes a lot deeper than that since it can mean a constant, crippling absence of any sensation related to happiness or satisfaction. In an effort to curtail the damage that this condition can do, a new app equipped with an artificial intelligence is being tested right now.
One of the most effective treatments for depression is talking to psychotherapists who will work with patients through their emotional distress. However, talking about depression is not easy and plenty of people often avoid it altogether. The new app called Woebot could provide an effective bridge in such situations by giving patients an avenue for a conversation with something that’s not human, Business Insider reports.
The app was created by Stanford University clinical psychologist Alison Darcy. According to her, Woebot was based on the treatment cognitive-behavioral therapy (CBT), which is intended to measure patient reactions to challenging scenarios. Darcy also notes that while Woebot can’t replace human therapists, it can still pave the way to recovery.
“What we haven’t done a good job of in [therapy] is give people an array of options — what about the people who aren’t ready to talk to another person?” Darcy said. “This is part of the idea of meeting people where they’re at.”
As to how effective the chatbot can even be, Darcy and her team published a study that showed a marked improvement in patients suffering from depression while interacting with Woebot. Naturally, more research is needed in order to make any kind of concrete conclusion with regards to using AI-powered chatbots as official psychological treatment tools.
However, this development does signal an encouraging direction in which therapists can go. The rate of suicide among teens and young adults has seen an alarming rise over recent years. This technology could pave the way to substantially reducing that.


SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Instagram Outage Disrupts Thousands of U.S. Users
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 



